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BACKGROUND
Stage III or IVA endometrial cancer carries a significant risk of systemic and loco­
regional recurrence.
METHODS
In this randomized phase 3 trial, we tested whether 6 months of platinum­based 
chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer 
relapse­free survival (primary end point) than six cycles of combination chemo­
therapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end 
points included overall survival, acute and chronic toxic effects, and quality of life.
RESULTS
Of the 813 patients enrolled, 736 were eligible and were included in the analysis 
of relapse­free survival; of those patients, 707 received the randomly assigned in­
tervention (346 received chemoradiotherapy and 361 received chemotherapy only). 
The median follow­up period was 47 months. At 60 months, the Kaplan–Meier 
estimate of the percentage of patients alive and relapse­free was 59% (95% confi­
dence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 
53 to 64) in the chemotherapy­only group (hazard ratio, 0.90; 90% CI, 0.74 to 
1.10). Chemoradiotherapy was associated with a lower 5­year incidence of vaginal 
recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and 
paraaortic lymph­node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 
to 0.66) than chemotherapy alone, but distant recurrence was more common in 
association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 
to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the 
chemoradiotherapy group and 227 patients (63%) in the chemotherapy­only group.
CONCLUSIONS
Chemotherapy plus radiation was not associated with longer relapse­free survival 
than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. 
(Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.)
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Women with locally advanced (In-ternational Federation of Gynecology and Obstetrics [FIGO] stage III or IVA) 
endometrial carcinoma are a heterogeneous group 
of patients who are at risk for both local and 
systemic disease recurrence. Clinical and patho­
logic factors affecting the risk of recurrence in­
clude the extent of abdominal and pelvic disease, 
histologic subtype, nodal involvement, presence 
of extranodal disease, and the completeness of 
surgical resection.1­4 Because of the heterogeneity 
of this patient population, a wide range of 5­year 
survival estimates has been reported, and an ap­
propriate postsurgery strategy remains unclear.5­8
Pelvic or whole abdominal radiotherapy has 
traditionally followed surgical resection.6,8 This 
approach prevented pelvic recurrence but was 
less effective in preventing systemic recurrence, 
which limited long­term survival. In a randomized 
trial conducted by the Gynecologic Oncology 
Group (GOG), GOG 122, chemotherapy was found 
to be superior to radiotherapy in treating locally 
advanced disease, and it thus became part of the 
standard treatment.9 However, if chemotherapy 
is given alone, the incidence of locoregional re­
currence approaches 20%,9 heralding subsequent 
distant metastasis and death. Therefore, it was 
logical to hypothesize that an approach that com­
bined the methods of treatment would improve 
outcomes by preventing local (pelvic) and distant 
recurrences.
This combined approach has been studied, 
but its efficacy relative to that of chemotherapy 
alone is not known. Patients with stage III endo­
metrial carcinoma treated with chemoradiother­
apy in the Radiation Therapy Oncology Group 
(RTOG) protocol 9708 trial had an estimated 
4­year overall survival of 77% and relapse­free 
survival of 72%.10 In the GOG 184 trial, which 
compared two chemotherapy regimens after tu­
mor volume–directed external­beam radiotherapy, 
the 3­year relapse­free survival estimates were 
62% to 64%.11 These results supported the fea­
sibility and efficacy of a combined treatment 
strategy.
The purpose of the current trial (GOG 258) 
was to evaluate the use of concurrent tumor 
volume–directed external­beam radiation ther­
apy and chemotherapy (i.e., chemoradiotherapy) 
as compared with the use of chemotherapy 
alone.9,11­13 Here, we report on relapse­free sur­
vival, the primary end point.
Me thods
Patients and Trial Oversight
We enrolled women who were 18 years of age or 
older and who had surgical stage III or IVA en­
dometrial carcinoma according to FIGO 2009 
staging criteria of any histologic subtype or had 
FIGO 2009 surgical stage I or II clear­cell or 
serous endometrial carcinoma and peritoneal 
washings that were positive for cancer cells. 
Hysterectomy and bilateral salpingo­oophorec­
tomy had to have been performed within 8 weeks 
before trial entry. No single residual tumor mass 
could be larger than 2 cm in greatest dimension. 
Pelvic and paraaortic lymph­node biopsy or dis­
section was optional. Normal organ function 
and a GOG performance status score of 2 or 
lower were required (scores range from 0 to 5, 
with higher scores reflecting greater disability). 
Patients with carcinosarcoma or recurrent endo­
metrial carcinoma were excluded.
The trial was conducted in accordance with 
applicable regulatory requirements and the prin­
ciples of the Declaration of Helsinki. Approval for 
the trial and for the informed­consent process 
from a local or central institutional review board 
or independent ethics committee was required 
for site participation. Patients provided written 
informed consent before enrollment.
Trial Design and End Points
This randomized, multicenter, phase 3 trial was 
designed with input from the Gynecologic Oncol­
ogy Group. The authors vouch for the accuracy 
and completeness of the data and for the fidelity 
of the trial to the protocol, available with the 
full text of this article at NEJM.org. The trial 
treatments were paid for by medical insurance, 
and the trial was supported by the National Can­
cer Institute. All the patients were registered 
through the National Cancer Institute Oncology 
Patient Enrollment Network. Treatment was ran­
domly assigned at the GOG Statistical and Data 
Center and was concealed until registration with 
verification of eligibility. Randomization was 
stratified according to age and the presence or 
absence of gross residual disease. The primary 
objective was to determine whether chemoradio­
therapy would be associated with a lower incidence 
of recurrence or death (i.e., longer relapse­free 
survival) than chemotherapy alone. Secondary ob­
jectives were between­group comparisons of over­
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all survival, the incidence and severity of acute 
and late toxic effects, and patient­reported qual­
ity of life.
Treatment and Assessments
The two treatment regimens were randomly as­
signed in a 1:1 ratio within permuted blocks. 
The chemoradiotherapy regimen consisted of cis­
platin at a dose of 50 mg per square meter of 
body­surface area given intravenously on days 1 and 
29 together with volume­directed external­beam 
radiation therapy, followed by carboplatin given 
at a dose to achieve an area under the concentra­
tion–time curve (AUC) of 5 to 6 plus paclitaxel at 
a dose of 175 mg per square meter every 21 days 
for four cycles, with granulocyte colony­stimu­
lating factor (G­CSF) support. The chemotherapy­
only regimen consisted of carboplatin (to achieve 
an AUC of 6) plus paclitaxel at a dose of 175 mg 
per square meter every 21 days for six cycles. In 
the chemoradiotherapy group, external­beam ra­
diation therapy was delivered to the pelvis with 
or without paraaortic fields. The planned total 
dose was 4500 cGy in 25 fractions at 180 cGy per 
fraction. Intensity­modulated radiotherapy and 
vaginal brachytherapy were allowed only in the 
chemoradiotherapy group. Disease assessments 
included computed tomography (CT) of the ab­
domen and pelvis and chest radiography at base­
line, the end of treatment, every 6 months for 
the first 2 years, and then annually up to 5 years. 
Safety assessments included recording of adverse 
events and concomitant medications, physical ex­
amination, and hematologic and chemical testing 
on the same schedule. Adverse events were grad­
ed with the use of the Common Terminology 
Criteria for Adverse Events (CTCAE), version 3.0. 
Annual follow­up was planned beyond 5 years.
The Trial Outcome Index of the Functional 
Assessment of Cancer Therapy (FACT) for endo­
metrial cancer (FACT­En) and the FACT/GOG–
neurotoxicity (NTX) subscale were used to mea­
sure quality of life and chemotherapy­induced 
neurotoxic effects (see the Supplementary Appen­
dix, available at NEJM.org). Two items from the 
FACT for colorectal cancer (FACT­C) combined 
with four items from the FACT­En Trial Outcome 
Index were used to assess gastrointestinal symp­
toms. Each item in the FACT­En Trial Outcome 
Index and the FACT/GOG­NTX subscale was 
scored with the use of a 5­point scale (0, not at all; 
1, a little bit; 2, somewhat; 3, quite a bit; 4, very 
much). The total FACT­En Trial Outcome Index 
score was calculated as the sum of the subscale 
scores if more than 80% of the items were an­
swered within each subscale. The total scores 
range from 0 to 120 for the FACT­En Trial Outcome 
Index and from 0 to 16 for the FACT/GOG­NTX 
subscale (see the Supplementary Appendix). A 
higher Trial Outcome Index, NTX, or gastrointes­
tinal score suggests better quality of life or fewer 
symptoms. The minimally clinically important dif­
ference is 6 points for the FACT­En Trial Outcome 
Index and 1.2 points for the FACT/GOG­NTX 
subscale.14 Assessments were completed before 
treatment (at baseline), 1 week after completing 
radiation therapy or before cycle 3 of chemo­
therapy, and 18 and 70 weeks after the start of 
treatment.
Quality Assurance
The trial was open to enrollment between June 
29, 2009, and July 28, 2014, and the data cutoff 
for analysis was March 9, 2017. The GOG Pathol­
ogy Committee verified histologic subtypes, grades, 
and stages for all patients. Eligibility, surgery, 
and radiation plans were reviewed centrally. The 
trial chairs monitored eligibility, chemotherapy 
delivery and modifications, adverse events, and 
radiographic assessments.
Statistical Analysis
The null hypothesis was that chemoradiotherapy 
would not achieve higher relapse­free survival 
percentages than chemotherapy alone. A 28.5% 
lower incidence of recurrence or death (relative 
hazard, 1.4, corresponding to relapse­free sur­
vival at 3 years of 61% in the chemotherapy­only 
group and 70% in the chemoradiotherapy group) 
was considered clinically significant. Observation 
of at least 252 recurrences or death events was 
needed to attain 85% statistical power with type I 
error for a one­tailed comparison at 0.05 for 
relapse­free and overall survival separately. Under 
the assumption of a decrease in the hazard of 
recurrence or death over time, a sample size of 
804 was targeted. Independence between relapse­
free or overall survival and the randomly assigned 
treatment was assessed with a stratified log­rank 
test in an intention­to­treat analysis including 
the eligible patients. Two interim analyses were 
planned when 42% (105) and 83% (210) of the 
expected number of recurrences or deaths had 
been reported. These were reported to the data 
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and safety monitoring board in September 2013 
and January 2016. No action was taken to alter 
the conduct of the trial on the basis of those 
interim analyses. A Kruskal–Wallis test correct­
ed for ties was used to compare the maximum 
grade of acute and late adverse effects of therapy 
(see the Supplementary Appendix). Between­
group differences in quality­of­life scores were 
assessed with a linear mixed model with adjust­
ment for the pretreatment score, assessment 
time point, and age at enrollment.
R esult s
Patients and Follow-up
Enrollment concluded with 813 patients; 77 were 
deemed ineligible, most commonly because of 
an inappropriate cancer stage or a lack of patho­
logical documentation. In addition, 29 eligible 
patients were never treated, with 24 of those hav­
ing been assigned to the chemoradiotherapy group. 
At the time of this report, all patients were no 
longer receiving the trial treatment and, after treat­
ment, 25 women had withdrawn consent for con­
tinued follow­up (12 in the chemoradiotherapy 
group and 13 in the chemotherapy­only group) 
(Fig. S1 in the Supplementary Appendix). There 
were 51 major protocol violations in 399 reviewed 
cases: 43 in the chemoradiotherapy group and 8 in 
the chemotherapy­only group; 15 in the chemo­
radiotherapy group were related to radiation de­
livery (see the Supplementary Appendix).
The median follow­up duration was 47 months; 
295 recurrence or death events were reported in 
the entire study population, and 271 were report­
ed among eligible patients. The safety analysis in­
cluded all eligible and treated patients, whereas 
the efficacy analysis included all eligible patients, 
regardless of whether they received treatment.
Characteristics of the patient and the tumors 
are shown in Table 1. A total of 72% of patients 
were between 50 and 69 years of age (median age, 
60 years), 90% identified as non­Hispanic, and 
77% identified as white. The performance status 
score was 0 for 74% of enrolled patients, and the 
endometrioid histologic type was predominant. 
Stratification factors were balanced between the 
treatment groups, with nearly 98% of patients 
having no gross residual disease. Surgery to re­
move lymph nodes was reported in more than 
94% of patients, with a median number of 13 
pelvic nodes and 3 paraaortic nodes removed.
Treatment
Overall, 75% of patients completed all prescribed 







Mean age (range) — yr 60.5 (31–88) 60 (31–85)
Race — no. (%)†
White 291 (78.6) 279 (76.2)
Black 37 (10.0) 42 (11.5)
Asian, other, or not specified 42 (11.4) 45 (12.3)
GOG performance status score — no. (%)‡
0 278 (75.1) 268 (73.2)
1 88 (23.8) 96 (26.2)
2 4 (1.1) 2 (0.5)
FIGO stage — no. (%)§
I or II 6 (1.6) 10 (2.7)
IIIA 70 (18.9) 81 (22.1)
IIIB 12 (3.2) 13 (3.6)
IIIC1 189 (51.1) 166 (45.4)
IIIC2 90 (24.3) 93 (25.4)
IVA 3 (0.8) 3 (0.8)
Histology and grade — no. (%)
Endometrioid, grade 1 87 (23.5) 79 (21.6)
Endometrioid, grade 2 103 (27.8) 118 (32.2)
Endometrioid, grade 3 64 (17.3) 61 (16.7)
Serous 66 (17.8) 65 (17.8)
Clear cell 10 (2.7) 12 (3.3)
Mixed epithelial or other 40 (10.8) 31 (8.5)
Gross residual disease — no. (%)
Absent 360 (97.3) 359 (98.1)
Present 10 (2.7) 7 (1.9)
Median BMI (range)¶ 32.0 (11.2–65.3) 32.9 (18–60.2)
BMI category — no. (%)
Normal or underweight 72 (19.5) 71 (19.4)
Overweight 84 (22.7) 81 (22.1)
Obesity class I, II, or III 214 (57.8) 214 (58.5)
*  There were no significant differences in baseline characteristics between the 
treatment groups. Percentages may not total 100 because of rounding.
†  Race was reported by the patient.
‡  A Gynecologic Oncology Group (GOG) performance status score of 2 or lower 
was required for enrollment (scores range from 0 to 5, with higher scores re-
flecting greater disability).
§  Stages were assigned according to the International Federation of Gynecology 
and Obstetrics (FIGO) 2009 classification; stages range from I to IV, with higher 
stages indicating more advanced spread of cancer.
¶  Body-mass index (BMI) is the weight in kilograms divided by the square of the 
height in meters.
Table 1. Characteristics of the Patients.*
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The majority of patients in the chemoradiother­
apy group received 45 cGy, intensity­modulated 
radiotherapy was used in 30% of cases, and 201 
patients received vaginal­cuff brachytherapy. Two 
cycles of cisplatin were coadministered with radia­
tion to more than 85% of patients in the chemo­
radiotherapy group, and 75% of the patients in 
that group received all four planned cycles of 
carboplatin and paclitaxel. In the chemotherapy­
only group, 85% of women received all six cycles 
during a median period of 17 weeks (Table S1 in 
the Supplementary Appendix). Two patients in the 
chemotherapy­only group received additional che­
motherapy and radiotherapy before progression; 
both patients discontinued the trial treatment 
early because of toxic effects. Between 8 and 
10% of patients discontinued treatment due to 
adverse events.
Toxicity
Table 2 shows acute adverse events, regardless 
of attribution to the trial intervention, in the 707 
eligible participants who initiated treatment. 
Grade 3, 4, or 5 adverse events were reported in 
202 patients (58%) in the chemoradiotherapy 
group and 227 patients (63%) in the chemotherapy­
only group. A grade 4 or higher acute adverse event 
occurred in 48 patients (14%) in the chemoradio­
therapy group and in 108 patients (30%) in the 
chemotherapy­only group. Two deaths were attrib­
uted to the trial treatment; both deaths occurred 
in the chemotherapy­only group (grade 5 sepsis 
and sudden death). Constitutional symptoms, 
fatigue, gastrointestinal events, renal or genito­
urinary events, and musculoskeletal events were 
significantly more frequent per grade in the 
chemoradiotherapy group. Hematologic adverse 
events were significantly more frequent and more 
severe in the chemotherapy­only group. Late toxic 
effects are summarized in Table S2 in the Sup­
plementary Appendix. A grade 4 or higher late 
adverse event was reported in 15 patients in the 
chemoradiotherapy group and in 11 patients in 
the chemotherapy­only group. No deaths that were 
determined by the trial chairs to be attributable to 
treatment occurred during the follow­up period.
Efficacy
The results with regard to the primary end point 
did not reach significance. At 60 months, the 
Kaplan–Meier estimate of the percentage of pa­
tients who were alive and recurrence­free was 
59% (95% confidence interval [CI], 53 to 65) in 
the chemoradiotherapy group and 58% (95% CI, 
53 to 64) in the chemotherapy­only group (haz­
ard ratio, 0.90; 90% Wald CI, 0.74 to 1.10). 
Adverse Event Chemoradiotherapy (N = 346) Chemotherapy Only (N = 361) P Value*
Any Grade Grade 3–5 Any Grade Grade 3–5
percent of patients
Constitutional symptom 87 6 80 2 0.004
Fatigue 85 5 75 2 <0.001
Cardiac event 16 3 19 4 0.71
Endocrine event 11 1 11 0 0.46
Gastrointestinal event 90 13 79 4 <0.001
Renal or genitourinary event 33 2 11 1 <0.001
Blood or bone marrow event 96 40 90 52 0.01
Infection 23 4 20 5 0.18
Lymphatic event 17 <1 16 <1 0.74
Musculoskeletal event 20 3 13 1 0.01
Metabolic or laboratory event 48 15 44 9 0.02
Neurologic event 76 7 80 5 0.99
Pulmonary event 31 2 26 1 0.83
Pain 70 8 68 5 0.04
*  P values for the between-group comparison of the maximum grade of adverse events were calculated with a Kruskal–
Wallis test corrected for ties.
Table 2. Acute Adverse Events.
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Therefore, the null hypothesis that chemoradio­
therapy is not superior to chemotherapy alone 
could not be rejected (P = 0.20 by one­tailed test) 
(Fig. 1). A sensitivity analysis indicated that the 
results observed in the eligible treated popula­
tion were consistent with the results among all 
eligible patients.
A total of 165 deaths have been reported to 
date — 86 in the chemoradiotherapy group and 
79 in the chemotherapy­only group. Of those 
deaths, 73% and 81%, respectively, were due to 
endometrial cancer progression. The data on over­
all survival are not sufficiently mature to allow 
comparison between the groups. Exploratory sub­
group analyses of relapse­free survival did not 
identify a subgroup of patients who may have 
benefited more from chemoradiotherapy than 
from chemotherapy alone, when age, histologic 
subtype, surgical stage, body­mass index, and 
the presence or absence of gross residual disease 
were taken into consideration (Fig. 2). The cumu­
lative incidence of vaginal disease recurrence at 
60 months of follow­up was 2% in the chemora­
diotherapy group and 7% in the chemotherapy­
only group (hazard ratio, 0.36; 95% CI, 0.16 to 
0.82) (Fig. 3A). The cumulative incidence of pel­
vic or paraaortic node recurrence at 60 months 
was 11% in the chemoradiotherapy group and 
20% in the chemotherapy­only group (hazard 
ratio, 0.43; 95% CI, 0.28 to 0.66) (Fig. 3B). The 
cumulative incidence of distant recurrence at 
60 months was 27% in the chemoradiotherapy 
group and 21% in the chemotherapy­only group 
(hazard ratio, 1.36; 95% CI, 1.00 to 1.86) 
(Fig. 3C). Coincident local and distant recur­
rences at first presentation were found in 2.2% 
of patients in the chemoradiotherapy group and 
in 4.9% of patients in the chemotherapy­only 
group; the sites of initial recurrence are shown 
in Table S3 in the Supplementary Appendix.
Quality of Life
Adherence to the quality­of­life assessments was 
95% at baseline, 90% at 6 weeks, 87% at 18 
weeks, and 78% at 70 weeks. The patients who 
could be evaluated were those with a valid base­
line assessment and at least one follow­up assess­
ment (332 in the chemoradiotherapy group and 
349 in the chemotherapy­only group). After ad­
justment for age and baseline scores, the least­
squares mean Trial Outcome Index score at 18 
weeks in the chemoradiotherapy group was 5.2 
points lower (97.5% CI, 2.7 to 7.8) than that in 
the chemotherapy­only group. The difference in 
this score remained significant at 70 weeks (3.4 
points lower in the chemoradiotherapy group; 
97.5% CI, 0.7 to 6.2) but did not exceed the 
6­point difference that had been preset as clini­
cally meaningful.14 Patients in both groups re­
ported symptoms of neurotoxicity in associa­
tion with treatment, but the least­squares mean 
FACT/GOG­NTX subscale score at 6 weeks among 
patients receiving chemotherapy only was 2.0 
points lower (97.5% CI, 1.4 to 2.6) than that in 
the chemoradiotherapy group (i.e., reflecting worse 
symptoms in the chemotherapy­only group), 
whereas patients receiving chemoradiotherapy re­
ported gastrointestinal symptoms at both 6 weeks 
and 18 weeks that were significantly worse than 
those in the chemotherapy­only group.
Discussion
The role of radiotherapy in local control of endo­
metrial carcinoma has been firmly established15­18; 
however, external­beam radiotherapy does not 
significantly improve overall survival in patients 
with early­stage, lower­risk disease. This was 
shown in both the Post Operative Radiation 
Therapy in Endometrial Carcinoma (PORTEC) 1 
trial and the GOG 99 trial,17,19 and its use in this 
context remains tailored to women who are con­
Figure 1. Relapse-free Survival.
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sidered to be at high risk for relapse.20 Because 
the risk of local relapse is higher among women 
with stage III uterine cancer than among those 
with early­stage disease,21 whole abdominal or 
pelvic radiotherapy has traditionally been incor­
porated in the standard postoperative approach 
for those with stage III disease.6,22 However, given 
the competing risk of distant metastasis, which 
has led to the implementation of chemotherapy 
as the standard of care,9 the role of radiotherapy 
remains uncertain. This trial prospectively eval­
uated the effect of combined chemotherapy plus 
radiotherapy in patients with stage III or IVA 
endometrial carcinoma as compared with the 
effect of chemotherapy alone. The results show 
that the combined regimen was not superior to 
chemotherapy alone in prolonging relapse­free 
survival, although locoregional relapses were less 
frequent than with chemotherapy alone.
An important strength of this trial is the rig­
orous definition of the patient population, which 
includes only patients with adnexal, lymph­node, 
and pelvic, nonperitoneal metastasis. With the 
revision of the FIGO staging system in 2009,23 
the trial was amended to exclude patients with 
peritoneal washings that were positive for cancer 
cells but with no evidence of extrauterine endo­
metrioid tumor, because such patients have bet­
ter outcomes than other patients with stage III 
disease.24,25 One exception was the group of pa­
tients with positive peritoneal washings and car­
cinoma of the clear­cell or serous histologic type, 
who are recognized as having a high risk of re­
currence26­30; these patients were included in this 
trial and represented less than 3% of the trial 
population. Nearly 75% of the patient population 
had endometrial carcinoma with lymph­node in­
volvement. Although surgical staging was not 
mandated, the majority of patients underwent 
full staging procedures.
Chemotherapy became the mainstay of treat­
ment for high­risk endometrial carcinoma after 
it became clear that distant metastasis is a key 
determinant of survival in patients with locally 
Figure 2. Subgroup Analysis According to Recognized Prognostic Factors.
Stages were assigned according to the International Federation of Gynecology and Obstetrics (FIGO) 2009 classification; stages range 
from I to IV, with higher stages indicating more advanced spread of cancer. BMI denotes body-mass index.
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advanced endometrial carcinoma. In the GOG 
122 trial, overall survival at 60 months was 10 per­
centage points higher among patients who received 
doxorubicin and platinum than among those 
treated with whole abdominal radiotherapy.9 The 
role of chemotherapy has been studied by other 
groups.5,31­33 Maggi et al. reported no significant 
difference in overall survival between patients 
who received cyclophosphamide, doxorubicin, and 
cisplatin (CAP) and those who received external­
beam radiotherapy.31 In the Japanese Gyneco­
logic Oncology Group trial, which involved pa­
tients with high­risk endometrial carcinoma, the 
percentages of patients surviving without pro­
gression (83% vs. 66%) and surviving overall 
(89% vs. 73%) were significantly higher among 
those who were randomly assigned to receive 
CAP than among those who received pelvic exter­
nal­beam radiotherapy.32 In a pooled analysis of 
trials conducted by the Nordic Society of Gyne­
cological Oncology (NSGO)–European Organi­
zation for Research and Treatment of Cancer 
(EORTC) and the Mario Negri Gynecologic On­
cology (MaNGO) group, sequential chemotherapy 
and pelvic external­beam radiotherapy approached 
statistical superiority to pelvic radiotherapy alone 
(hazard ratio, 0.69; P = 0.07).33 Adjuvant chemo­
radiotherapy was compared with external­beam 
radiotherapy in patients with early­stage high­
risk and stage III endometrial carcinoma in the 
recently reported PORTEC 3 trial. Overall sur­
vival was not affected by the addition of chemo­
therapy, but the combined regimen improved 
relapse­free survival relative to radiotherapy (75% 
vs. 68%), with most of the benefit found in pa­
tients with stage III disease.34
Several regimens have been tested in patients 
with locally advanced or metastatic endometrial 
carcinoma, including those regimens named 
above, paclitaxel–doxorubicin–cisplatin, and carbo­
platin–paclitaxel.11,13,31,33,35 Because carboplatin–
paclitaxel induced similar outcomes with less 
toxicity,12 this regimen was adopted in clinical 
practice and in this trial. More than 85% of pa­
tients in this trial who were in the chemotherapy­
only group received the planned six cycles, 
whereas only 63% completed all cycles of treat­
ment in GOG 122, as a result of treatment­related 
toxic effects. Full delivery of chemotherapy was 
diminished by the addition of radiotherapy, with 
only 75% of women completing the four planned 
courses in the chemoradiotherapy group. These 
results are similar to previous observations in 
GOG 184, in which only 80% of patients com­
pleted the intended chemotherapy after radio­
therapy,11 and may have contributed to the higher­
than­anticipated frequency of distant metastases.
The results of our trial could lead to specula­
tion that external­beam radiotherapy should be 
delivered after completion of chemotherapy. Single­
institution retrospective studies using a “sand­
wich” radiotherapy–chemotherapy approach have 
suggested a reasonable side­effect profile and 
estimated 5­year overall and distant metastasis­
free survival of 77% and 85%, respectively.36,37 
Because these results have not been validated 
prospectively, they should not be adopted with­
out further study. Likewise, substituting vaginal 
brachytherapy for external­beam radiotherapy may 
be tempting, but because the risk of vaginal recur­
rence is low, intracavitary radiotherapy should 
be reserved for women who are at high risk for 
vaginal relapse. Finally, the short­term and long­
term effects of treatment on quality of life should 
be considered. Although acute toxic effects were 
more common in the chemoradiotherapy group 
than in the chemotherapy­only group in our trial, 
most were low­grade and reversible on treatment 
discontinuation. Chronic toxic effects included 
diarrhea, lymphedema, and musculoskeletal events 
and were more common with chemoradiother­
apy, which affected patient­reported outcomes. 
Late second cancers are also a risk.
In summary, in this randomized trial, the 
combined regimen of chemotherapy plus radia­
tion did not provide a benefit over chemotherapy 
alone with respect to relapse­free survival in pa­
tients with stage III or IVA endometrial carci­
noma. Our data are compatible with the hypoth­
esis from previous studies that completion of 
chemotherapy is important for the prevention 
of distant relapse.
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Figure 3 (facing page). Cumulative Risk of Recurrence.
The insets show the same data on an enlarged y axis.
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